My "second love" with the spike"
Release time:
2020-07-22
My "Second Love" with Peak
Remember that it was 2002 5# August 8 . I first reported to Peak Pharmaceutical, and my destination was Linhai Jianfeng Haizhou Pharmaceutical Factory, a subsidiary factory of the pharmaceutical industry. At that time, Haizhou Pharmaceutical had overgrown weeds at the factory gate, and "desolation" was the first impression it gave me. In the old factory area, I only stayed for one month, and the next month I went to Du Qiao to build a new factory. Although some details can't be remembered now, the "weeding incident" that occurred that month is still impressive. At that time, the greening work in the factory was contracted by an employee, because the enterprise was facing relocation due to poor efficiency, the mentality of the employees was floating, and some managers did not dare to take care of it, so I pulled out a handful of weeds and put them on the employee's desk, forcing him to pull the weeds. Although this seemed unpleasant at the beginning, it was the so-called "no fight, no acquaintance", and later this employee became my good friend. This employee's name is Wu Shunfa. Some old employees may still remember that he is also an excellent salesman.
2002 5 to 2005 was my first working experience in Jianfeng Pharmaceutical, mainly responsible for preparing for the construction of a new factory. Those two and a half years can be described as a turbulent period for the pharmaceutical industry. From the pharmaceutical company to Haizhou Pharmaceutical, the leadership team changed several times. However, with the joint efforts of my colleagues and I, we still completed the preparation for the new factory and the relocation of equipment, and successfully passed the bulk drug GMP examination in 5 before the deadline for passing the GMP certification stipulated by the State Food and Drug Administration in 2004 . That experience meant a lot to my personal growth, and I'm always grateful for it. Although later for some reason left the peak, but in the peak of the day, left me are good memories. Although the conditions at the time of preparation were very poor, lunch was often a bowl of pickle soup in the canteen of the construction team, but when the leaders at all levels of the company came to inspect the work, they always cared about our life, so that I still miss the taste of braised three green crabs. More than ten years have passed in a flash. Although the external environment has changed greatly and the production of peak pharmaceutical preparations has developed and expanded, the development of API has returned to the starting point.
, when there was another chance to return to the peak family, I decisively chose to return. Because I have been wandering outside for many years, I still can't forget the surprise of receiving a "good wife award" at the end of 2002 and the happiness of my family, as well as the careful guidance of the pharmaceutical project department to our preparatory team that year. It's the spikes that help me grow. Besides, in the more than ten years since I left the peak, the group leaders have visited me many times during the inspection and exchange of peer companies, which fully reflects the humanistic feelings of a listed company. Now, I have returned to work in Peak Pharmaceutical for more than two years. This is still the peak I am familiar with, but it is a little strange. The perfect enterprise system is not the same as that of that year. This time, as the person in charge of the pharmaceutical preparation for the establishment of the API business department, I got more help from peak managers during the investment inspection work of one and a half years. No matter the concept of leading investment and development of enterprises, or the quality of professionals, I feel deeply. In particular, the "innovative" spirit of enterprise, let me have a real experience. I understand that the slightly conservative peak in the original impression actually contains deep innovation genes. The new generation of leaders is leading the peak to rejuvenate and move towards new glory.
Now, our Jianfeng Pharmaceutical Co., Ltd. has regained its platform for the development of API business-Shanghai Beika Pharmaceutical Technology Co., Ltd., and has two Anhui factories. I am full of confidence in the future development of the API production base. Up to now, the peak has gone through
years of development. I write this article to my small partners and new colleagues now. I also use this to encourage us to contribute to the "100-year peak. (Lou Xiaohua)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page